Menorrhalgia Market Report 2025

The menorrhalgia market size has grown strongly in recent years. It will grow from $20.61 billion in 2024 to $21.97 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth observed in the historical period can be attributed to factors such as the rising incidence of hormonal imbalances, increased awareness about menorrhalgia, a higher prevalence of gynecological disorders, the growing incidence of endometrial cancer, and better availability of over-the-counter medications.

The menorrhalgia market size is expected to see strong growth in the next few years. It will grow to $28.0 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth projected for the forecast period is driven by factors such as the expanding geriatric population, an increase in the use of intrauterine devices, technological advancements, a growing preference for minimally invasive procedures, and a rising focus on preventive healthcare. Key trends expected during this period include advancements in treatment options, a focus on sustainable and eco-friendly therapies, further technological progress, improvements in hormone delivery methods, and the development of innovative treatment modalities.

The increasing prevalence of hormonal imbalances is expected to drive the growth of the menorrhagia market in the future. Hormonal imbalances occur when there is an excess or deficiency of hormones in the body, leading to various health issues such as weight fluctuations, mood changes, fatigue, and reproductive problems. Factors such as modern lifestyles, environmental influences, and medical conditions contribute to these imbalances. Poor diet, high stress levels, and lack of physical activity can disrupt hormone production and regulation. Hormonal imbalances can trigger menorrhagia (heavy menstrual bleeding) by interfering with the normal regulation of the menstrual cycle and impacting the uterine environment. For instance, in January 2025, the World Health Organization highlighted polycystic ovary syndrome as a significant public health concern, affecting 6-13% of women of reproductive age annually. Consequently, the increasing occurrence of hormonal imbalances is driving market growth for menorrhagia.

Leading companies in the menorrhagia market are focusing on the development of innovative solutions, such as hormonal intrauterine devices (IUDs), to provide effective and long-term treatment options. A hormonal IUD is a small, T-shaped device placed inside the uterus that releases progestin to prevent pregnancy by thickening cervical mucus, thinning the uterine lining, and inhibiting ovulation. For example, in October 2022, Bayer AG, a German pharmaceutical company, received regulatory approval in Europe for Mirena, a hormonal IUD used for contraception and the treatment of idiopathic menorrhagia. This device continuously releases levonorgestrel, helping to reduce menstrual blood loss by thinning the uterine lining and reducing menstrual flow, offering a practical, long-term solution for managing heavy menstrual bleeding without the need for daily medication or surgery.

In January 2025, Hologic Inc., a US-based health technology company, acquired Gynesonics Inc. for an undisclosed sum. This acquisition allows Hologic to expand its portfolio of minimally invasive solutions for treating uterine fibroids and heavy menstrual bleeding, enhancing healthcare options for women. Gynesonics Inc. is a US-based medical device company specializing in systems for treating menorrhagia.

Major players in the menorrhalgia market are AbbVie Inc., Bayer HealthCare Pharmaceuticals Inc. (a division of Bayer AG), Baxter International Inc., Boston Scientific Corporation, Johns Hopkins Health System Corporation, Aegea Medical Inc., Emory Healthcare Inc., Hologic Inc., Dr. Reddy's Laboratories Ltd., Meril Life Sciences Pvt. Ltd., ASKA Pharmaceutical Holdings Co. Ltd., Ferring Pharmaceuticals Group, Minerva Infra Tech Private Limited, Roivant Sciences Ltd., Xanodyne Pharmaceuticals Inc., Pregna International Ltd., HLL Lifecare Limited, Actiza Pharmaceutical Pvt. Ltd., Wellona Pharma, OCON Healthcare Ltd.

North America was the largest region in the menorrhalgia market in 2024. The regions covered in menorrhalgia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the menorrhalgia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Menorrhagia, also known as menorrhalgia, refers to excessively heavy or prolonged menstrual bleeding. It is characterized by menstrual cycles lasting longer than seven days or involving blood loss greater than 80 milliliters. This condition can result in fatigue, anemia, and discomfort. Menorrhagia may be caused by factors such as hormonal imbalances, uterine fibroids, polyps, or other underlying health issues.

The primary therapeutic options for menorrhagia are hormonal and non-hormonal agents. Hormonal treatments help manage menorrhagia by regulating hormones to reduce uterine contractions, control the growth of the endometrium, and alleviate both pain and bleeding. These medications can be administered through various methods, including oral, vaginal, transdermal, intrauterine, and other routes. They are available through various distribution channels, including retail pharmacies, hospital pharmacies, and online pharmacies.

The menorrhalgia market research report is one of a series of new reports that provides menorrhalgia market statistics, including the menorrhalgia industry global market size, regional shares, competitors with the menorrhalgia market share, detailed menorrhalgia market segments, market trends, and opportunities, and any further data you may need to thrive in the menorrhalgia industry. This menorrhalgia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The menorrhalgia market consists of revenues earned by entities by providing services such as medical consultation, diagnostic testing, and medication management. The market value includes the value of related goods sold by the service provider or included within the service offering. The menorrhagia market also consists of sales of products including medications, medical devices, and supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.